Discovery and development of safe-in-man broad-spectrum antiviral agents.

Antiviral drug BSAAs Broad-spectrum antiviral agents Drug discovery and development Virus

Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 24 01 2020
revised: 07 02 2020
accepted: 11 02 2020
pubmed: 23 2 2020
medline: 25 7 2020
entrez: 22 2 2020
Statut: ppublish

Résumé

Viral diseases are one of the leading causes of morbidity and mortality in the world. Virus-specific vaccines and antiviral drugs are the most powerful tools to combat viral diseases. However, broad-spectrum antiviral agents (BSAAs, i.e. compounds targeting viruses belonging to two or more viral families) could provide additional protection of the general population from emerging and re-emerging viral diseases, reinforcing the arsenal of available antiviral options. Here, we review discovery and development of BSAAs and summarize the information on 120 safe-in-man agents in a freely accessible database (https://drugvirus.info/). Future and ongoing pre-clinical and clinical studies will increase the number of BSAAs, expand the spectrum of their indications, and identify drug combinations for treatment of emerging and re-emerging viral infections as well as co-infections.

Identifiants

pubmed: 32081774
pii: S1201-9712(20)30076-X
doi: 10.1016/j.ijid.2020.02.018
pmc: PMC7128205
pii:
doi:

Substances chimiques

Antiviral Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

268-276

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Références

Front Immunol. 2019 Mar 19;10:531
pubmed: 30941148
Antiviral Res. 2015 Nov;123:120-31
pubmed: 26408355
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Nucleic Acids Res. 2019 Jan 8;47(D1):D1102-D1109
pubmed: 30371825
Biol Open. 2018 Jan 29;7(1):
pubmed: 29378701
Br J Pharmacol. 2018 Jan;175(2):181-191
pubmed: 28685814
Nat Commun. 2013;4:1418
pubmed: 23361009
Euro Surveill. 2020 Feb;25(5):
pubmed: 32019636
J Virol. 2019 Apr 3;93(8):
pubmed: 30700611
Antiviral Res. 2016 Sep;133:23-31
pubmed: 27451344
J Pharmacol Pharmacother. 2011 Apr;2(2):74-9
pubmed: 21772764
Antiviral Res. 2018 Feb;150:20-29
pubmed: 29224735
J Cell Mol Med. 2018 Dec;22(12):5807-5815
pubmed: 30338908
Med Chem. 2017;13(8):787-795
pubmed: 28359234
Cell Stem Cell. 2017 Aug 3;21(2):274-283.e5
pubmed: 28736217
Genome Med. 2018 Apr 24;10(1):32
pubmed: 29690921
Front Pharmacol. 2018 Sep 20;9:1068
pubmed: 30294274
Vision Res. 1967 Mar;7(3):243-51
pubmed: 5613294
J Immunol Methods. 2014 Aug;410:60-79
pubmed: 24709389
Antiviral Res. 1983 Mar;3(1):17-24
pubmed: 6307139
Antimicrob Agents Chemother. 2014 May;58(5):2905-11
pubmed: 24614368
Clin Microbiol Rev. 2016 Jul;29(3):695-747
pubmed: 27281742
Trends Pharmacol Sci. 2002 Jan;23(1):13-8
pubmed: 11804646
Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72
pubmed: 17278083
Sci Rep. 2017 Jan 18;7:40920
pubmed: 28098253
Sci Transl Med. 2017 Jun 28;9(396):
pubmed: 28659436
Virology. 2018 Feb;515:29-37
pubmed: 29223788
Antiviral Res. 2016 Nov;135:81-90
pubmed: 27742486
Cell Res. 2019 Apr;29(4):265-273
pubmed: 30814679
Viruses. 2019 Feb 20;11(2):
pubmed: 30791609
Crit Rev Microbiol. 2013 Nov;39(4):325-61
pubmed: 22978742
J Immunol Methods. 2014 Jul;409:131-46
pubmed: 24291345
Postgrad Med. 2011 Sep;123(5):194-204
pubmed: 21904102
Virology. 2004 Jun 20;324(1):67-73
pubmed: 15183054
Antimicrob Agents Chemother. 2019 Jan 29;63(2):
pubmed: 30455237
J Med Chem. 2011 Dec 22;54(24):8670-80
pubmed: 22059983
J Gen Virol. 2008 Sep;89(Pt 9):2157-2166
pubmed: 18753225
PLoS Pathog. 2018 Jul 20;14(7):e1007188
pubmed: 30028873
Vaccine. 2017 Jan 11;35(3):469-480
pubmed: 27908639
Clin Transl Sci. 2017 May;10(3):133-142
pubmed: 28160433
Nat Rev Drug Discov. 2019 Jan;18(1):41-58
pubmed: 30310233
PLoS One. 2018 Mar 22;13(3):e0194880
pubmed: 29566079
Chemotherapy. 1999 Jan-Feb;45(1):48-55
pubmed: 9876209
Emerg Infect Dis. 2017 Nov;23(11):
pubmed: 28949285
Antiviral Res. 2017 Sep;145:82-86
pubmed: 28736077
PLoS One. 2016 Mar 10;11(3):e0151616
pubmed: 26963103
Antiviral Res. 2017 Mar;139:117-128
pubmed: 28049006
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Nat Chem Biol. 2016 May;12(5):361-6
pubmed: 27018887
Viruses. 2017 Sep 25;9(10):
pubmed: 28946654
Curr Protoc Microbiol. 2013;Chapter 15:Unit 15G.4
pubmed: 23686828
EBioMedicine. 2019 Jan;39:315-331
pubmed: 30579862
Sci Rep. 2018 Jun 12;8(1):8989
pubmed: 29895962
Curr Opin Pharmacol. 2019 Oct;48:92-98
pubmed: 31454708
Science. 2014 Mar 7;343(6175):1246980
pubmed: 24604203
J Virol. 2017 Mar 29;91(8):
pubmed: 28148798
Antiviral Res. 2018 Jun;154:174-182
pubmed: 29698664
Virology. 2011 Feb 5;410(1):216-27
pubmed: 21131014
J Hepatol. 2017 Mar;66(3):494-503
pubmed: 27746336
Nucleic Acids Res. 2019 Jan 8;47(D1):D963-D970
pubmed: 30371892
Future Sci OA. 2015 Nov 01;1(4):FSO63
pubmed: 28031915
Virus Res. 2014 Jun 24;186:20-31
pubmed: 24361981
Science. 1972 Aug 25;177(4050):705-6
pubmed: 4340949
Nat Microbiol. 2018 May;3(5):611-621
pubmed: 29632368
J Virol. 2019 May 29;93(12):
pubmed: 30918074
Cell Host Microbe. 2016 Aug 10;20(2):259-70
pubmed: 27476412
Immunity. 2017 Mar 21;46(3):446-456
pubmed: 28314593
J Virol Methods. 2016 Jul;233:56-61
pubmed: 27016178
Antiviral Res. 2014 Jun;106:125-34
pubmed: 24680954
Nat Commun. 2018 May 29;9(1):2090
pubmed: 29844387
Antiviral Res. 2016 Sep;133:41-9
pubmed: 27468950
Philos Ethics Humanit Med. 2009 Jan 15;4:2
pubmed: 19146696
Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6
pubmed: 15215127
J Hepatol. 2019 Aug;71(2):289-300
pubmed: 31077792
Front Microbiol. 2016 Feb 04;7:80
pubmed: 26870031
J Biol Chem. 2012 Oct 12;287(42):35324-32
pubmed: 22910914
J Infect Dis. 2016 Dec 15;214(suppl 5):S482-S487
pubmed: 27920178
Nat Med. 2016 Oct;22(10):1101-1107
pubmed: 27571349
Sci Transl Med. 2014 Sep 10;6(253):253ps10
pubmed: 25210060
J Am Chem Soc. 2010 Jun 16;132(23):7976-81
pubmed: 20527935
J Virol. 2018 Nov 27;92(24):
pubmed: 30282713
Pharmacol Res Perspect. 2015 Jun;3(3):e00149
pubmed: 26171228
Science. 2015 Apr 17;348(6232):282-3
pubmed: 25883340
Methods Mol Biol. 2013;1030:407-25
pubmed: 23821285
Mol Cell Proteomics. 2016 Oct;15(10):3203-3219
pubmed: 27486199
Nat Rev Microbiol. 2017 Jun;15(6):351-364
pubmed: 28420884
Viruses. 2018 Oct 30;10(11):
pubmed: 30380760
Lancet. 2018 Nov 10;392(10159):1859-1922
pubmed: 30415748
mBio. 2018 Dec 18;9(6):
pubmed: 30563895
ACS Infect Dis. 2018 Feb 9;4(2):88-92
pubmed: 29298032
Curr Opin Infect Dis. 2015 Dec;28(6):596-602
pubmed: 26524332
Emerg Microbes Infect. 2012 Dec;1(12):e46
pubmed: 26038413
Cell Rep. 2017 Jan 17;18(3):804-815
pubmed: 28099856
PLoS One. 2013 Nov 04;8(11):e78425
pubmed: 24348901
Ann N Y Acad Sci. 1977 Mar 4;284:410-7
pubmed: 280143
PLoS Pathog. 2012;8(10):e1002976
pubmed: 23133371
Br J Pharmacol. 2011 Sep;164(2):344-57
pubmed: 21418188
Front Immunol. 2019 Oct 04;10:2186
pubmed: 31636628
PLoS Pathog. 2016 Jun 23;12(6):e1005717
pubmed: 27336364
Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082
pubmed: 29126136
Sci Rep. 2017 Mar 23;7:44676
pubmed: 28333153
Int J Mol Sci. 2019 Feb 14;20(4):
pubmed: 30769780
PLoS Negl Trop Dis. 2018 Aug 20;12(8):e0006715
pubmed: 30125275
Antiviral Res. 2017 Feb;138:68-78
pubmed: 27939840
Antiviral Res. 2018 Aug;156:92-101
pubmed: 29920300
Viruses. 2012 Nov 19;4(11):3209-26
pubmed: 23202522
Cell Discov. 2018 Jun 5;4:31
pubmed: 29872540
Cell Rep. 2017 Oct 10;21(2):517-532
pubmed: 29020636
J Virol Methods. 2007 Aug;143(2):169-74
pubmed: 17420056
Molecules. 2015 Jun 22;20(6):11474-89
pubmed: 26111177
Viruses. 2019 Oct 18;11(10):
pubmed: 31635418
Clin Biochem. 1990 Aug;23(4):267-77
pubmed: 2225455
Drug Discov Today. 2019 May;24(5):1224-1228
pubmed: 30980905

Auteurs

Petter I Andersen (PI)

Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 7028 Trondheim, Norway.

Aleksandr Ianevski (A)

Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 7028 Trondheim, Norway.

Hilde Lysvand (H)

Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 7028 Trondheim, Norway.

Astra Vitkauskiene (A)

Department of Laboratory Medicine, Lithuanian University of Health Science, 44307 Kaunas, Lithuania.

Valentyn Oksenych (V)

Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 7028 Trondheim, Norway.

Magnar Bjørås (M)

Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 7028 Trondheim, Norway.

Kaidi Telling (K)

Institute of Technology, University of Tartu, 50090 Tartu, Estonia.

Irja Lutsar (I)

Institute of Medical Microbiology, University of Tartu, Tartu 50411, Estonia.

Uga Dumpis (U)

Latvian Biomedical Research and Study Centre, Riga 1067, Latvia.

Yasuhiko Irie (Y)

Institute of Technology, University of Tartu, 50090 Tartu, Estonia.

Tanel Tenson (T)

Institute of Technology, University of Tartu, 50090 Tartu, Estonia.

Anu Kantele (A)

Helsinki University Hospital (HUS) and University of Helsinki, Helsinki 00290, Finland.

Denis E Kainov (DE)

Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 7028 Trondheim, Norway; Institute of Technology, University of Tartu, 50090 Tartu, Estonia; Institute for Molecular Medicine Finland, FIMM, University of Helsinki, 00014 Helsinki, Finland. Electronic address: denis.kainov@ntnu.no.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH